Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?

Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response. Methods: We included 52 patients and 25 healthy controls. Serum levels of tumor necrosis fact...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2004
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/27040
Acceso en línea:
https://doi.org/10.1016/j.semarthrit.2003.11.002
https://repository.urosario.edu.co/handle/10336/27040
Palabra clave:
Systemic lupus erythematosus
Cytokines
TNF-
IL-10
IL12
Autoantibodies
SLEDAI.
Rights
License
Restringido (Acceso a grupos específicos)
id EDOCUR2_0ecbf4db2394d9bac051d62f24aa0bcb
oai_identifier_str oai:repository.urosario.edu.co:10336/27040
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling c0b2f7ab-631c-42db-8f4f-b9c3b929b540bf0a793a-b98c-4d91-9906-cae3cca64282c5e15d68-2e79-46cc-994c-608ea4c1dc2311dd66da-4e02-4f6f-9171-5c31eb777d1b75a6f055-1328-4b82-bda4-794e3b86dfb6194747786002020-08-19T14:40:50Z2020-08-19T14:40:50Z2004-06Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response. Methods: We included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor (TNF) , interferon (IFN) , interleukin (IL)-12p70, IL-10, and IL-4, as well as anti-DNA, -Ro, -La, -RNP, and -Sm antibodies were determined by enzyme-linked immunosorbent assay. Disease activity was recorded according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and classified as very active (SLEDAI > 13), moderately active (SLEDAI: 3-12), or inactive (SLEDAI < 2). Results: The mean age of the patients was 34.2 12.6 years, and the mean duration of disease was 4.9 7.6 years. Twelve patients (23%), 20 patients (34.5%), and 20 patients (34.5%) had highly, moderately, and inactive SLE, respectively. Levels of IFN-, TNF- , and IL-12 were significantly higher in patients than in healthy controls (P < .03), as well as the IL-12/IL-10, IL-12/IL-4, IFN/IL-10, IFN/IL-4, TNF/IL-10, and TNF/IL-4 ratios (P < .01), suggesting a major participation of Th1 over Th2 cytokines. Nevertheless, a direct correlation between Th1 (IFN- and TNF- ) and Th2 (IL-4 and IL-10) cytokines was observed in patients (r > .5, P < .01), indicating a mutual Th1-Th2 participation. TNF- levels and the TNF/IL-10 ratio were higher in patients with inactive disease compared with patients with very active disease and controls (P < .04). IL-12 levels and IL-12/IL-4, as well as IL-12/IL-10, ratios were higher in patients with very active disease than in those with inactive SLE and controls (P < .01). IL-10 levels were associated with anti-DNA, anti-Ro, and anti-La response (P < .01). Conclusion: Our results suggest that TNF- could be a protective factor in SLE patients, whereas IL-12p70 participates in disease activity and IL-10 influences the autoimmune response (autoantibody production).application/pdfhttps://doi.org/10.1016/j.semarthrit.2003.11.002ISSN: 0049-0172EISSN: 1532-866Xhttps://repository.urosario.edu.co/handle/10336/27040engElsevier413No. 6404Seminars in Arthritis and RheumatismVol. 33Seminars in Arthritis and Rheumatism, ISSN: 0049-0172; EISSN: 1532-866X, Vol.33, No.6 (2004); pp. 404-413https://www.sciencedirect.com/science/article/pii/S0049017203002142?via%3DihubRestringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecSeminars in Arthritis and Rheumatisminstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURSystemic lupus erythematosusCytokinesTNF-IL-10IL12AutoantibodiesSLEDAI.Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?Citocinas Th1 / Th2 en pacientes con lupus eritematoso sistémico: ¿es protector el factor de necrosis tumoral alfa?articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Gomez, DianaCorrea, PaulaGómez, Luis MiguelCadena, JoséMolina JoséAnaya, Juan-Manuel10336/27040oai:repository.urosario.edu.co:10336/270402021-08-10 21:21:47.631https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
dc.title.TranslatedTitle.spa.fl_str_mv Citocinas Th1 / Th2 en pacientes con lupus eritematoso sistémico: ¿es protector el factor de necrosis tumoral alfa?
title Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
spellingShingle Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
Systemic lupus erythematosus
Cytokines
TNF-
IL-10
IL12
Autoantibodies
SLEDAI.
title_short Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
title_full Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
title_fullStr Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
title_full_unstemmed Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
title_sort Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
dc.subject.keyword.spa.fl_str_mv Systemic lupus erythematosus
Cytokines
TNF-
IL-10
IL12
Autoantibodies
SLEDAI.
topic Systemic lupus erythematosus
Cytokines
TNF-
IL-10
IL12
Autoantibodies
SLEDAI.
description Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response. Methods: We included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor (TNF) , interferon (IFN) , interleukin (IL)-12p70, IL-10, and IL-4, as well as anti-DNA, -Ro, -La, -RNP, and -Sm antibodies were determined by enzyme-linked immunosorbent assay. Disease activity was recorded according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and classified as very active (SLEDAI > 13), moderately active (SLEDAI: 3-12), or inactive (SLEDAI < 2). Results: The mean age of the patients was 34.2 12.6 years, and the mean duration of disease was 4.9 7.6 years. Twelve patients (23%), 20 patients (34.5%), and 20 patients (34.5%) had highly, moderately, and inactive SLE, respectively. Levels of IFN-, TNF- , and IL-12 were significantly higher in patients than in healthy controls (P < .03), as well as the IL-12/IL-10, IL-12/IL-4, IFN/IL-10, IFN/IL-4, TNF/IL-10, and TNF/IL-4 ratios (P < .01), suggesting a major participation of Th1 over Th2 cytokines. Nevertheless, a direct correlation between Th1 (IFN- and TNF- ) and Th2 (IL-4 and IL-10) cytokines was observed in patients (r > .5, P < .01), indicating a mutual Th1-Th2 participation. TNF- levels and the TNF/IL-10 ratio were higher in patients with inactive disease compared with patients with very active disease and controls (P < .04). IL-12 levels and IL-12/IL-4, as well as IL-12/IL-10, ratios were higher in patients with very active disease than in those with inactive SLE and controls (P < .01). IL-10 levels were associated with anti-DNA, anti-Ro, and anti-La response (P < .01). Conclusion: Our results suggest that TNF- could be a protective factor in SLE patients, whereas IL-12p70 participates in disease activity and IL-10 influences the autoimmune response (autoantibody production).
publishDate 2004
dc.date.created.spa.fl_str_mv 2004-06
dc.date.accessioned.none.fl_str_mv 2020-08-19T14:40:50Z
dc.date.available.none.fl_str_mv 2020-08-19T14:40:50Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.semarthrit.2003.11.002
dc.identifier.issn.none.fl_str_mv ISSN: 0049-0172
EISSN: 1532-866X
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/27040
url https://doi.org/10.1016/j.semarthrit.2003.11.002
https://repository.urosario.edu.co/handle/10336/27040
identifier_str_mv ISSN: 0049-0172
EISSN: 1532-866X
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 413
dc.relation.citationIssue.none.fl_str_mv No. 6
dc.relation.citationStartPage.none.fl_str_mv 404
dc.relation.citationTitle.none.fl_str_mv Seminars in Arthritis and Rheumatism
dc.relation.citationVolume.none.fl_str_mv Vol. 33
dc.relation.ispartof.spa.fl_str_mv Seminars in Arthritis and Rheumatism, ISSN: 0049-0172; EISSN: 1532-866X, Vol.33, No.6 (2004); pp. 404-413
dc.relation.uri.spa.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0049017203002142?via%3Dihub
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.rights.acceso.spa.fl_str_mv Restringido (Acceso a grupos específicos)
rights_invalid_str_mv Restringido (Acceso a grupos específicos)
http://purl.org/coar/access_right/c_16ec
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.source.spa.fl_str_mv Seminars in Arthritis and Rheumatism
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167474518622208